Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 6/20 | 0.42 |
| ▸ | CTNNB1 | P35222 | 12/20 | 0.38 |
| ▸ | TCF7L2 | Q9NQB0 | 12/20 | 0.38 |
| ▸ | CCR5 | P51681 | 2/20 | 0.37 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.36 |
| ▸ | FASN | P49327 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5027234 | 1.00 | CCR2 (0.42) | CCR2CTNNB1TCF7L2CCR5HRH4 | |
| SCHEMBL5033684 | 0.92 | CCR2 (0.42) | CCR2CCR5HRH4CYP2D6KCNH2 | |
| SCHEMBL5033678 | 0.92 | CCR2 (0.42) | CCR2CCR5HRH4CYP2D6KCNH2 | |
| SCHEMBL5233058 | 0.83 | CTNNB1 (0.36) | CCR2CTNNB1TCF7L2HRH4FASN | |
| SCHEMBL5029654 | 0.73 | CCR2 (0.51) | CCR2CCR5CYP2D6KCNH2 | |
| SCHEMBL5027260 | 0.70 | CTNNB1 (0.44) | CTNNB1TCF7L2HRH4 | |
| SCHEMBL5030562 | 0.70 | CCR2 (0.41) | CCR2CYP2D6KCNH2 | |
| SCHEMBL5030568 | 0.70 | CCR2 (0.41) | CCR2CYP2D6KCNH2 | |
| SCHEMBL5033546 | 0.70 | CCR2 (0.43) | CCR2CCR5CYP2D6KCNH2 | |
| SCHEMBL5033548 | 0.70 | CCR2 (0.43) | CCR2CCR5CYP2D6KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7378409-B2 | Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-27 | — | — | US | disclosed |
| EP-1656138-A4 | SUBSTITUTED CYCLOALKYAMINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL MYERS SQUIBB CO (US) | 2007-04-18 | — | — | EP | disclosed |
| EP-1656138-A2 | SUBSTITUTED CYCLOALKYAMINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Bristol-Myers Squibb Company (US) | 2006-05-17 | — | — | EP | disclosed |
| WO-2005020899-A2 | SUBSTITUTED CYCLOALKYAMINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-03-10 | — | — | WO | disclosed |
| US-20050054626-A1 | Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054626-A1 | Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity | CCL11, CCR1, CCR2 | CCR2 3/4885CTNNB1 4439/4885TCF7L2 1658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.